Lexicon Pharmaceuticals (LXRX) Net Cash Flow (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Net Cash Flow data on file, last reported at $3.8 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 199.87% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 112.5% increase from a year earlier, with the FY2025 full-year figure at -$3.3 million, down 107.54% from the prior year.
• Net Cash Flow for Q1 2026 stood at $3.8 million, up from -$15.3 million in the prior quarter.
• Over the last five years, Net Cash Flow for LXRX reached as high as $76.3 million in Q2 2023 and fell as low as -$81.2 million in Q3 2023.
• Historically, Net Cash Flow has averaged $177882.4 across 5 years, with a median of -$2.6 million in 2022.
• Across the five-year window, Net Cash Flow tumbled 3002.26% in 2023 and soared 2754.03% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $27.5 million in 2022, then slumped by 95.1% to $1.3 million in 2023, then soared by 2279.91% to $32.1 million in 2024, then slumped by 147.75% to -$15.3 million in 2025, then surged by 124.55% to $3.8 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $3.8 million in Q1 2026, -$15.3 million in Q4 2025, and $28.3 million in Q3 2025.